Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 58Squamous Cell Carcinoma of Head and Neck 57Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

Abiraterone Acetate 5enzalutamide 4abiraterone 3Prednisone 3apalutamide 2Nivolumab 2Docetaxel 2pembrolizumab 1niraparib 1darolutamide 1cabazitaxel 1Pluvicto 1Omeprazole 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms, Castration-Resistant × Docetaxel × Clear all
NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 2 Terminated
10 enrolled 15 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡